n | (%) | |
---|---|---|
Demographics | ||
Maternal age at conception (years±SD)* | 28.7 | (±4.4) |
Parity status | ||
0 | 137 | (63.8) |
1 | 58 | (27.7) |
≥2 | 18 | (8.5) |
Clinical situation | ||
NYHA class I | 161 | (75.6) |
NYHA class II | 51 | (23.9) |
NYHA class III | 1 | (0.5) |
Past medical history | ||
Sustained symptomatic bradyarrhythmia or tachyarrhythmia requiring treatment | 19 | (8.9) |
Left heart obstruction (PG>30 mm Hg or AVA<1.5 cm2 or MVA<2 cm2) | 14 | (6.6) |
Left heart obstruction (PG>50 mm Hg or AVA<1.0 cm2) | 4 | (1.9) |
Systemic ventricular systolic dysfunction (EF<40%) | 7 | (3.3) |
Cardiac medication before pregnancy† | 33 | (15.5) |
Systemic AV valve regurgitation‡ | 4 | (2.3) |
Pulmonary AV valve regurgitation‡ | 12 | (6.9) |
Mechanical valve prosthesis | 11 | (5.2) |
In origin cyanotic heart disease | 57 | (26.8) |
Severe PR and/or depressed subpulmonary ventricular EF | 24 | (11.3) |
Smoking prepregnancy | 44 | (21.4) |
Pacemaker | 8 | (3.8) |
Congestive heart failure | 5 | (2.4) |
Cerebrovascular accident | 3 | (1.4) |
Hypertension | 14 | 6.6 |
Medication use preconception | ||
None | 180 | (84.5) |
Angiotensin-converting enzyme inhibitor | 2 | (0.9) |
Antiplatelet drugs | 2 | (0.9) |
β-blockers | 26 | (12.2) |
Calcium-channel blocker | 5 | (2.3) |
Digoxin | 1 | (0.5) |
Diuretics | 0 | (0.0) |
Vitamin K antagonists/Heparin | 15 | (7.0) |
N=213 pregnancies.
*Mean (±SD).
†With the exception of vitamin K antagonists/Heparin.
‡Moderate/severe.
AV, atrioventricular; AVA, aortic valve area; MVA, mitral valve area; NYHA, New York Heart Association functional class; PG, peak gradient; PR, pulmonary regurgitation.